UK interleukin inhibitors market was valued at $2,426.4 million in 2025 and is projected to reach $6,006.7 million by 2035, growing at a CAGR of 9.5% during the forecast period (2026–2035). Interleukin inhibitors are targeted biologic therapies designed to modulate specific inflammatory pathways and are widely used in the treatment of autoimmune and chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, atopic dermatitis, asthma, and inflammatory bowel disease. Market growth is driven by the rising prevalence of immune-mediated disorders, increasing adoption of biologics over conventional systemic therapies, and expanding reimbursement support through the National Health Service (NHS).
Browse the full report description of “UK Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/uk-interleukin-inhibitors-market
The market is experiencing strong momentum across the UK, supported by early diagnosis initiatives, growing patient access to advanced biologic therapies, and the presence of well-established specialty care networks. Key trends shaping the interleukin inhibitors landscape include the increasing uptake of IL-17, IL-23, and IL-5 targeted therapies, preference for self-administrable subcutaneous formulations, and the development of next-generation molecules with improved safety and dosing profiles. In addition, the entry of biosimilars, real-world evidence generation, and personalized treatment approaches are collectively enhancing affordability and long-term adoption.
According to PMC, the adoption and clinical use of interleukin inhibitors especially IL-6 neutralizing biologics like tocilizumab and sarilumab is increasing in hospitals, rheumatology clinics, and specialist care settings across the United Kingdom as part of targeted therapy for inflammatory diseases such as rheumatoid arthritis.
Key Innovators Driving UK Interleukin Inhibitors Transformation
The key players in the UK interleukin inhibitors market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Regeneron Pharmaceuticals, Inc., among others. These companies are driving innovation through novel cytokine-targeting biologics, combination therapies, and expanded indications across dermatology, gastroenterology, and respiratory medicine, shaping the future of immune-mediated disease management in the UK.
Market Coverage
Key questions addressed by the report.
UK Interleukin Inhibitors Market Report Segment
By Product Type
By Application
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-interleukin-inhibitors-market